Advances in Acute Myeloid Leukemia (AML) Management: Focus on Secondary AML and Older Patients with AML
Clinicians need to be informed about therapeutic advances and necessary supportive care precautions to aid in their efficacious and safe incorporation into clinical practice for the appropriate AML patient subpopulations. 
Recorded Presentation from the NCCN Pharmacy Updates: New Targets and Treatment Options for Acute Myeloid Leukemia
Recent advances have led to rational drug development as new therapeutically actionable molecular targets have emerged. It is important for clinicians to be aware of how to incorporate these novel treatment options into clinical practice in ways that achieve meaningful patient outcomes, as well as best practices for providing supportive care and patient education.
Novel and Emerging Treatment Strategies for Acute Myeloid Leukemia
Advances in the molecular understanding of acute myeloid leukemia (AML) has enhanced risk stratification and optimized therapeutic strategies. However, there is still a need for improved therapeutic strategies to combat AML disease progression, especially in older patients. Informing clinicians about therapeutic advances and necessary supportive care precautions will aid in their efficacious and safe incorporation into clinical practice for the appropriate AML patient subpopulations.
AML: Expert Guidance on Current Standards and New Directions in Patient Care
The goal of this activity is to improve and accelerate the awareness, understanding, and integration of current best practices in the treatment of AML.
NCCN Pharmacy Updates: New Targets and Treatment Options for Acute Myeloid Leukemia
Recent advances have led to rational drug development as new therapeutically actionable molecular targets have emerged. It is important for clinicians to be aware of how to incorporate these novel treatment options into clinical practice in ways that achieve meaningful patient outcomes, as well as best practices for providing supportive care and patient education.
AML: Expert Guidance on Current Standards and New Directions in Patient Care

The goal of this activity is to improve and accelerate the awareness, understanding, and integration of current best practices in the treatment of AML.

 

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

Therapeutic Advances in First-Line Acute Myeloid Leukemia Management

There is a need for improved therapeutic strategies to combat acute myeloid leukemia (AML) disease progression.

Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Acute Myeloid Leukemia

Novel and Emerging Treatment Options for Acute Myeloid Leukemia

Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Acute Myeloid Leukemia

Novel and Emerging Treatment Options for Acute Myeloid Leukemia

Recorded Presentations from the NCCN 2018 Congress Webinar Series: Acute Leukemia

During 2017, the US Food and Drug Administration (FDA) approved three new AML drugs and brought back a fourth that had been withdrawn in 2010.

Pages

Subscribe to RSS - Acute Myelogenous Leukemia